A B S T R A C T The mechanism by which ristocetin induces platelet agglutination in the presence of the von Willebrand factor was studied by chemically altering ristocetin and a similar antibiotic, vancomycin, by reaction with a water-soluble carbodiimide in the presence of glycine methyl ester at pH 4.75. Altering ristocetin's phenolic groups (which are thought to be important in its peptide-binding properties) resulted in a loss of both plateletagglutinating and antibiotic activities. Restoring the phenolic groups with hydroxylamine restored both activities.
A B S T R A C T The mechanism by which ristocetin induces platelet agglutination in the presence of the von Willebrand factor was studied by chemically altering ristocetin and a similar antibiotic, vancomycin, by reaction with a water-soluble carbodiimide in the presence of glycine methyl ester at pH 4.75. Altering ristocetin's phenolic groups (which are thought to be important in its peptide-binding properties) resulted in a loss of both plateletagglutinating and antibiotic activities. Restoring the phenolic groups with hydroxylamine restored both activities.
Vancomycin has antibiotic and peptide-binding properties similar to ristocetin's, but differs structurally in having a free carboxyl group and thus a less positive charge at neutral pH. It does not induce platelet agglutination and actually inhibits ristocetininduced agglutination. Reacting vancomycin with the water-soluble carbodiimide resulted in alteration of phenolic groups and permanent conversion of the carboxyl to a neutral derivative. Restoring the phenolic groups with hydroxylamine (but leaving the carboxyl neutralized) produced a compound with charge properties similar to ristocetin's which induced platelet agglutination as ristocetin does.
These data suggest both a binding requirement (mediated through phenolic groups) and a strong positive charge requirement for ristocetin-induced agglutination. The data are consistent with a model
INTRODUCTION
In 1971, Howard and Firkin observed that the antibiotic ristocetin induced platelet aggregation in normal platelet-rich plasma (1) . It is now known that this phenomenon requires: (a) a plasma factor activity absent or decreased in von Willebrand's disease (1) (2) (3) , and (b) a platelet factor missing or decreased in the Bernard-Soulier syndrome (4) . This platelet factor is not affected by formalinization (5) but is decreased by proteolytic enzyme treatment (6) . Whereas previous studies (7) (8) (9) , including our own (10, 11) , support an electrostatic mechanism of aggregation, the precise manner in which ristocetin interacts with these two factors remains unknown.
The molecular structure of ristocetin (which actually is composed of two closely related compounds, ristocetins A and B) is not completely known, but current data suggest that it consists of a cyclic dipeptide aglycone to which various sugars (including a unique aminosugar) are attached (12) . Titration analysis revealed phenolic and amino groups, with an isoionic point of 8.2-8.3 (13) .
Studies of ristocetin's antimicrobial activity showed that it can bind to specific peptides with configurations similar or identical to intermediates in bac-absolute requirement for a terminal, ionized carboxyl group on the peptide, and titration analysis indicated that ristocetin's phenolic groups take part in the binding reaction. McFarlane recently showed that these ristocetin-binding peptides can inhibit ristocetin-induced platelet agglutination (15) , suggesting that the peptides can compete for the available ristocetin.
Vancomycin is an antibiotic similar to ristocetin in structure (16) , antimicrobial spectrum (17) , mechanism ofaction, and peptide-binding properties (18) . We have previously shown that it does not aggregate platelets as ristocetin does (19) , and a preliminary report indicated that it actually inhibits ristocetin-induced platelet aggregation (20) . Vancomycin, unlike ristocetin, contains a single ionizable carboxyl group, in addition to its amino and phenolic groups (13) . This results in vancomycin having a less positive net charge than ristocetin at neutral pH. Since we previously postulated that ristocetin's ability to induce aggregation depended upon it having a net positive charge (based on the coincidence ofthe upper pH limit of ristocetin-induced platelet aggregation [8.3-8.5] with its isoionic point [8.2-8.3] ), this charge difference may account for vancomycin's inability to induce agglutination.
To investigate the mechanism of ristocetin-induced agglutination, we modified both ristocetin and vancomycin by reaction with the water-soluble carbodiimide 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (EDC),1 at pH 4.75, in the presence of the nucleoIAbbreviations used in this paper: EDC, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide; OD, optical density; PRP, platelet-rich plasma. phile glycine methyl ester. Under these conditions, both phenolic and carboxyl groups will react (21, 22) , yielding an 0-aryl isourea and the neutral glycine methyl ester derivative of the carboxylic acid, respectively ( Fig. 1) . Both reactions consume hydrogen ions so that the amount of acid required to maintain a constant pH can be used as a rough measure of the extent of the reaction. The phenolic group can be regenerated from the 0-aryl isourea by reaction with hydroxylamine (22) , but the carboxylic acid derivative is not reversible with hydroxylamine. Thus, with ristocetin, which contains phenolic but not carboxylic acid groups, the reaction will alter the phenolic groups which can then be regenerated with hydroxylamine. Vancomycin, on the other hand, will undergo modification of both its phenolic and carboxylic acid groups. Subsequent reaction with hydroxylamine will regenerate the phenolic groups but not the carboxylic acid group. Since the carboxyl derivative is uncharged at neutral pH, the net charge of the vancomycin will be made more positive, that is, more like ristocetin's. Thus, these reactions permitted us to investigate the importance of the phenolic groups (presumed to be important in the binding reactions) and the net molecular charge in ristocetin-induced agglutination. The number of these free ions was calculated from the volume of solution and the free concentrations of the ions as determined from the titration curve of H20. All titration data were reported without adjustment except the hydroxylamine-treated vancomycin-EDC derivative where, for purposes of comparison of dissociation constants, the values were reduced by a factor of 0.38 to make the total micromoles of the H+ dissociated equivalent to that ofthe untreated vancomycin. Since the shapes of the curves in the alkaline region were identical (as contrasted to the shift to the left in pK's of the vancomycin-EDC derivative), the differences in total H+ dissociated probably reflected a higher concentration of the derivative as a result of a reduction in extinction coefficient from the introduction of the carboxyl group modification.
METHODS
Spectroscopic studies to test for phenolic group alterations in ristocetin were conducted in a Gilford spectrophotometer (model 240, Gilford Instrument Laboratories, Inc., Oberlin, Ohio). Ristocetin and its derivatives were prepared in deionized water to a final volume of 1 ml at approximately the same OD280 and adjusted to pH 7 by the addition of 1 N NaOH (less than 1 Iul). Optical density readings were taken at multiple wavelengths between 270 and 305 nm on each sample. The samples were then adjusted to pH 11 with 1 N NaOH (less than 2.5 ,ul for any sample) and the readings repeated.
The water-soluble carbodiimide reactions were carried out at pH 4.75 according to the method of Hoare and Koshland (21). 5 ml of aqueous solutions of ristocetin (15 or 25 mg/ml) or vancomycin fraction IV (6.1 mg/ml) were made 1 M in glycine methyl ester and placed in a water-jacketed reaction vessel maintained at 24°C. The solutions were adjusted to pH 4.75 and the reaction initiated by adding 0.5 ml of 1 M EDC adjusted to pH 4.75. The solution was stirred constantly by a magnetic stirrer and the pH maintained at 4.75 by manual addition of 1 N HCI with a micrometer buret. At 1-min intervals, the volume of acid added to maintain the pH was recorded. Aliquots were removed periodically for monitoring OD280 and platelet-clumping activity. The progress of the reaction was followed by the rate of consumption of acid. This was rapid at first and then diminished to near zero at approximately 110-130 min. The low molecular weight reactants were removed from the antibiotic by diafiltration in an Amicon device fitted with a 1,000-mol wt cut-off membrane (UM-2). Diafiltration was accomplished either by repeated cycles of concentration followed by the addition of deionized water, or the use of a reservoir which continuously replaced the diafiltrate with deionized water. The process was terminated and the samples concentrated when the conductivity of the diafiltrate decreased to a constant value (90-350 ,u mho/cm). The reaction of the phenolic groups with EDC was reversed by mixing equal volumes of the diafiltered and concentrated antibiotic-EDC derivative with 1 M hydroxylamine, pH 7.0, at 25°C for 4 h. The samples were then diafiltered (to remove the low molecular weight hydroxylamine) and concentrated as described above.
Ristocetin-induced platelet agglutination was performed by modifying the previously described (10) formalin-fixed platelet assay for von Willebrand factor. To test the clumping ability of ristocetin during the EDC reaction, 25-Al aliquots of the reaction mixture were added to test tubes containing 0.4 ml of washed, formalinized platelets (adjusted to 300,000/mm3) and 50 ,ul of a reference plasma (either a pool of 10 normal citrated plasmas or a lyophilized reference plasma [QPak, Hyland Div., Travenol Laboratories, Inc., Costa Mesa, Calif.]). The time for macroscopic clumping to occur was then recorded. Preliminary experiments revealed that glycine methyl ester had no effect on the assay at the concentrations used in the reaction. A log-log standard curve was constructed from the clumping times of ristocetin-I M glycine methyl ester at the same concentration used in the reaction and dilutions of this solution prepared in 1 M glycine methyl ester. The clumping time produced by aliquots of the reaction mixture at intervals after the reaction was begun 304
B. S. Coller and H. R. Gralnick could then be converted into a percentage of the original clumping activity of the ristocetin. In a similar manner, the restoration of clumping activity produced by reaction with hydroxylamine was followed by adding 50,l (used early in the reaction for low levels of clumping activity) or 20 ,l (used late in the reaction for higher levels of clumping activity) of the reaction mixture to the platelet-reference plasma mixture and detennining the clumping time. Preliminary experiments showed that hydroxylamine, at the dose used, had no effect on the assay. The percentage of activity restored was derived from two standard curves of clumping times of dilutions of ristocetin-hydroxylamine in 0.5 M hydroxylamine using either 50-or 20-,ul aliquots. To be certain that the restored clumping activity was not due to a nonspecific plasma protein precipitation reaction, severe von Willebrand plasma (<3% von Willebrand factor) was substituted for the reference plasma. plasma. These studies employed 0.4 ml of platelets, 5 gl of vancomycin fraction IV at 22.6 mg/ml, 50 gl of undiluted reference plasma, and 5 ,A of ristocetin (50 mg/ml).
Platelet aggregation was performed on citrated plateletrich plasma in a Chrono-Log aggregometer (Chrono-Log Corp., Havertown, Pa.) as previously described (10) . All samples were maintained at pH 7.70+0.05 U by controlling the PCO2 environment as previously described (10), and a Tefloncoated stir bar (2.4 x 4.75-mm) was used for all studies (24) . 25 ,ul of water or vancomycin fraction IV in water (15, 7.5, and 3.75 mg/ml) was added to samples of PRP (0.4 ml; 300,000 platelets/mm3) which had previously established a base line optical density (OD). After exactly 1 min, 15 ,ul of ristocetin (50 mg/ml) was added and the change in OD was recorded. Quantitation was obtained by measuring the initial slope of aggregation and expressing it as OD units/minute. 
RESULTS
In all four experiments, reacting ristocetin with EDC led to a decrease in platelet-agglutinating activity. The results of one of these experiments are shown in Fig. 2 . The amount of acid added was a measure of the extent of the reaction. The ability of ristocetin to agglutinate platelets decreased to 90% of its original activity immediately after the addition of the 1/10 vol of EDC and then continued to decrease over time. By 25 min, the clumping activity was reduced to the lower limit of sensitivity of the assay (21%) and so could not be accurately measured fuirther. At the end of the reaction and after removing the EDC and glycine methyl ester, the antibiotic activity of the altered ristocetin was 24% (average of two experi- Ristocetin-induced platelet aggregation of PRP was also inhibited by vancomycin fraction IV as evidenced by a decrease in the initial slope of aggregation. The control value was 5.8 OD U/min, whereas at final vancomycin concentrations of 0.22, 0.43, and 0.85 mg/ml the initial slope decreased to 4.6, 4.0, and 3.3 U/min, respectively.
The electrometric titration data on vancomycin and its derivatives are shown in Fig. 6 was not affected by the hydroxylamine. The resulting compound has charge properties very similar to those of ristocetin in the neutral pH range. Reaction of vancomycin with EDC in the presence of glycine methyl ester decreased the antibiotic activity to 9% of its original value. Subsequent reaction with hydroxylamine restored the antibiotic activity to 50% (average of two experiments) of its original value.
The platelet aggltutinating ability of vancomycin fraction IV and its derivatives in the presence of plasma is shown in Table III . Neither vancomycin nor vancomycin + EDC agglutinated platelets in the presence of normal plasma. However, after stubsequent reaction of the vancomycin + EDC with hydroxylamine, the derivative did agglutinate platelets in the presence of normal plasma. This agglutination was not supported by three plasmas from patients with severe von Willebrand's disease. The agglutination was not dependent on procoagulant factor VIII since two plasma from patients with hemophilia with less than 1% procoagulant factor VIII supported agglutination. Both antibiotic and agglutinating activities, as well as the physicochemical characteristics of the compound, were partially or completely restored by subsequent reaction with hydroxylamine, lending further support to a phenolic group alteration. These data suggest that the phenolic group-dependent peptide-binding reaction previously implicated in ristocetin's antibiotic activity may also be crucial in its plateletagglutinating properties. Vancomycin, which has antibiotic and peptidebinding properties similar to ristocetin, does not induce platelet agglutination as ristocetin does. In fact, our studies confirm the preliminary report (20) that vancomycin inhibits the ristocetin-induced platelet agglutination phenomenon in both the PRP and formalinized platelet systems. This inhibition appears to be specific for ristocetin-induced aggregation since, in our unpublished studies, vancomycin at a final concentration of 0.5 mg/ml did not inhibit ADP, epinephrine, or collagen-induced aggregation. Although not definitive, our studies suggest that the inhibition is of a competitive nature since increasing concentrations of ristocetin diminished the inhibition. In addition, vancomycin's inhibition seems to be produced by an effect on the platelet rather than on the von Willebrand factor since the inhibition increased over time when vancomycin was incubated with platelets but not with plasma. One possibility is that vancomycin occupied the ristocetin-binding sites on the platelet and thus prevented ristocetin's binding. This is reasonable since both antibiotics have similar binding properties.
In addition to a binding requirement, our studies on ristocetin and vancomycin also support a requirement for a net positive charge for platelet agglutination induction. We previously postulated that ristocetin required a net positive charge to induce agglutination since the upper pH limit of ristocetin-induced platelet agglutination (8.3-8.5 ) coincided with the isoionic point of ristocetin (8.2-8.3 ). Our studies confirm that vancomycin has a free carboxyl group in addition to amino and phenolic groups, and thus has a less positive net charge than ristocetin at neutral pH. Two previous titration studies on vancomycin differed as to the number of amino groups on the molecule. This is important since it will make a difference in the net charge in the neutral pH range. Lomakina et al. (13) concluded that there were two amino groups and that the isoionic point of the antibiotic was 8.0. Nieto and Perkins (18) concluded that there was only a single amino group. Since more recent direct biochemical data by Smith et al. (25) support the presence of two amino groups in vancomycin, we favor this view. Reacting vancomycin with EDC resulted in a loss of antibiotic activity, and physicochemical analysis showed alterations of both phenolic and carboxyl groups. Subsequent reaction with hydroxylamine regenerated the phenolic groups and restored half of the original antibiotic activity but left the carboxyl group untitratable, that is, neutralized, with the glycine methyl ester derivative. This demonstrates that vancomycin's antibiotic activity is not completely dependent on the presence of its free carboxyl group and this was anticipated since ristocetin has antibiotic activity even though it lacks a free carboxyl group. In the neutral pH range, the hydroxylamine-treated vancomycin + EDC compound has charge properties very similar to ristocetin's since both compounds have net charges of +2 at a pH of approximately 5.5 (as compared to a pH of about 3.75 for Ristocetin-Induced Platelet Agglutination 309 unaltered vancomycin), will be uncharged at a pH between 8 In constructing a model of ristocetin-induced platelet agglutination, it is crucial to know which of the three elements (platelet, von Willebrand factor, ristocetin) interact specifically with each of the others. Unfortunately little direct experimental data is available. In our study, vancomycin's inhibition seemed to be based on its interaction with platelets since preincubation with platelets enhanced the inhibition but preincubation with plasma did not. If vancomycin is, in fact, acting as competitive inhibitor by occupying ristocetin-binding sites, then it is most probable that ristocetin has a direct interaction with the platelet. Other indirect evidence for this interaction derives from the observation that the addition of ristocetin to formalinized platelets stirred in an aggregometer in the absence of plasma results in a decrease in the light transmittance of the platelet suspension (9) . Direct evidence for the binding of ristocetin to the platelet surface awaits the availability of a suitable tracer molecule.
If ristocetin does bind to the platelet, it may do so by a mechanism similar to its binding properties with peptides. The latter phenomenon has an absolute requirement for a terminal ionized carboxyl group on the peptide (14) . Seaman Still unresolved, however, is the molecular events accounting for the attachment of one platelet to another. We believe that several lines of evidence support the hypothesis that the von Willebrand factor itself may act as a bridging molecule between platelets. Firstly, biochemical studies on the von Willebrand factor in our own and other laboratories (32) (33) (34) have identified it as a macromolecular (molecular weight > 1.2 million) glycoprotein made up of identical subunits held together by disulfide bonds. Both its large size and repetitive subunit structure make it analogous to an IgM molecule and, like the latter, these features make it an ideal candidate for causing agglutination. In addition, we and others have identified the intimate relationship between the von Willebrand factor and the platelet (35, 36) and it is likely that a specific platelet receptor mechanism (37) which recognizes the carbohydrate portion of the von Willebrand factor is involved in this association (38) .
Since the von Willebrand factor also carries a net negative charge at neutral pH, there will also be a net repulsive force between it and the platelet. It is possible that ristocetin selectively reduces the negative charge near the platelet's von Willebrand factor receptor and thus facilitates this interaction. Recent reports showing a requirement for ristocetin in the binding of exogenous von Willebrand factor to platelets are consistent with this mechanism (39, 40) .
As a unifying working hypothesis, we propose that in the normal state the electrostatic repulsion between platelets prevents their getting close enough to each other to be bridged by the von Willebrand factor. When ristocetin is added, it binds, via its phenolic groups, to the platelet surface, most likely at protein-associated free carboxyl groups. Being positively charged, the bound ristocetin reduces the net negative charge on the platelet surface and permits closer contact between platelets. This, in turn, permits the von Willebrand factor to bridge between platelets resulting in agglutination. Alternatively or additionally, ristocetin may selectively reduce the negative charge near the von Willebrand factor receptor, permitting the fluid phase von Willebrand factor to more easily bind to the platelet to initiate agglutination. Vancomycin can also bind to the platelet surface, but since its own free carboxyl group makes it less positively charged, it cannot reduce the platelet's negative charge as ristocetin does. By occupying the ristocetin-binding sites on the platelet surface, it actually inhibits ristocetin-induced agglutination. When its charge properties are made more like those of ristocetin (while still preserving its binding properties) it can induce agglutination in the presence of the von Willebrand factor as ristocetin does.
Data derived from studies of the Bernard-Soulier syndrome might appear to conflict with the above hypothesis. The platelets in this disorder have decreased sialic acid content and a less negative electrophoretic mobility (41) , which should result in a reduction in electrostatic repulsion between platelets and enhanced agglutination. Instead, these platelets do not agglutinate with ristocetin even in the presence of von Willebrand factor. However, the membrane glycoprotein which is deficient and/or abnormal in this disorder (6) appears to be crucial in the attachment of von Willebrand factor to the platelet since these platelets will not bind von Willebrand factor even in the presence of ristocetin (40) . Thus, despite the electrostatic advantage the platelets have for agglutination, the inability to bind the bridging molecule is of greater importance in determining whether agglutination will or will not occur.
